EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Brigatinib in NF2 -Related Schwannomatosis with Progressive Tumors

Scott R Plotkin iD, Kaleb H Yohay, Phioanh L Nghiemphu, Christine T Dinh, Dusica Babovic-Vuksanovic, Vanessa L Merker, Annette Bakker, Geoffrey Fell, Lorenzo Trippa, Jaishri O Blakeley iD, INTUITT-NF2 Consortium

New England Journal of Medicine · 27.06.2024 · 390 (24) · 2284-2294

DOI: 10.1056/nejmoa2400985 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 27.06.2024. Verfasst von Scott R Plotkin und 10 weiteren Autor:innen. Beteiligte Einrichtung: From Massachusetts General Hospital and Harvard Medical School (S.R.P., V.L.M.) and the Dana-Farber Cancer Institute (G.F., L.T.) - all in Boston; th…. Hauptthemen laut MEDLINE: Pyrimidines, Organophosphorus Compounds, Neurofibromatosis 2, Antineoplastic Agents. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: NCI NIH HHS, Andrea Cahill Foundation, Takeda Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesOrganophosphorus CompoundsNeurofibromatosis 2Antineoplastic AgentsAdultDisease ProgressionAdolescentNeurofibromatosesAdministration, OralHumansNeurilemmomaMaleYoung AdultSkin NeoplasmsQuality of LifeChildTumor BurdenFemaleProtein Kinase InhibitorsMagnetic Resonance ImagingMiddle AgedHearing Disorders

Substanzen

Antineoplastic AgentsbrigatinibOrganophosphorus CompoundsProtein Kinase InhibitorsPyrimidines

Autor:innen und Institutionen

  • From Massachusetts General Hospital and Harvard Medical School (S.R.P., V.L.M.) and the Dana-Farber Cancer Institute (G.F., L.T.) - all in Boston; the NYU Grossman School of Medicine (K.H.Y.) and the Children's Tumor Fo…

ORCID-Profile: Scott R Plotkin, Jaishri O Blakeley

Förderung

  • NCI NIH HHS
  • Andrea Cahill Foundation
  • Takeda Oncology
  • Children’s Tumor Foundation

Zitieren

APA

Plotkin, S. R., Yohay, K. H., Nghiemphu, P. L., Dinh, C. T., Babovic-Vuksanovic, D., Merker, V. L., Bakker, A., Fell, G., Trippa, L., Blakeley, J. O., & INTUITT-NF2 Consortium (2024). Brigatinib in NF2 -Related Schwannomatosis with Progressive Tumors. New England Journal of Medicine, 390(24), 2284-2294. https://doi.org/10.1056/nejmoa2400985

Vancouver

Plotkin SR, Yohay KH, Nghiemphu PL, Dinh CT, Babovic-Vuksanovic D, Merker VL, et al. Brigatinib in NF2 -Related Schwannomatosis with Progressive Tumors. New England Journal of Medicine. 2024;390(24):2284-2294. doi:10.1056/nejmoa2400985

BibTeX
@article{Plotkin2024,
  author = {Plotkin, Scott R and Yohay, Kaleb H and Nghiemphu, Phioanh L and Dinh, Christine T and Babovic-Vuksanovic, Dusica and Merker, Vanessa L and Bakker, Annette and Fell, Geoffrey and Trippa, Lorenzo and Blakeley, Jaishri O and INTUITT-NF2 Consortium, INTUITT-NF2 Consortium},
  title = {Brigatinib in NF2 -Related Schwannomatosis with Progressive Tumors},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {24},
  pages = {2284--2294},
  doi = {10.1056/nejmoa2400985}
}
Kostenlos starten →